SG160330A1 - Pharmaceutical forms with improved pharmacokinetic properties - Google Patents

Pharmaceutical forms with improved pharmacokinetic properties

Info

Publication number
SG160330A1
SG160330A1 SG201001165-8A SG2010011658A SG160330A1 SG 160330 A1 SG160330 A1 SG 160330A1 SG 2010011658 A SG2010011658 A SG 2010011658A SG 160330 A1 SG160330 A1 SG 160330A1
Authority
SG
Singapore
Prior art keywords
pharmacokinetic properties
pharmaceutical forms
improved pharmacokinetic
vardenafil
plateau
Prior art date
Application number
SG201001165-8A
Other languages
English (en)
Inventor
Peter Serno
Roland Heinig
Kerstin Pauli
Yutaka Hayauchi
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36264023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG160330(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of SG160330A1 publication Critical patent/SG160330A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG201001165-8A 2005-03-01 2006-02-16 Pharmaceutical forms with improved pharmacokinetic properties SG160330A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005009240A DE102005009240A1 (de) 2005-03-01 2005-03-01 Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften

Publications (1)

Publication Number Publication Date
SG160330A1 true SG160330A1 (en) 2010-04-29

Family

ID=36264023

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001165-8A SG160330A1 (en) 2005-03-01 2006-02-16 Pharmaceutical forms with improved pharmacokinetic properties

Country Status (39)

Country Link
US (2) US8613950B2 (el)
EP (2) EP1858490B1 (el)
JP (1) JP5122984B2 (el)
KR (1) KR101360526B1 (el)
CN (2) CN101141950B (el)
AR (2) AR053552A1 (el)
AT (1) ATE552828T1 (el)
AU (1) AU2006220100B2 (el)
BR (1) BRPI0609375A2 (el)
CA (1) CA2599617C (el)
CR (2) CR9339A (el)
CY (1) CY1112874T1 (el)
DE (1) DE102005009240A1 (el)
DK (1) DK1858490T3 (el)
DO (1) DOP2006000049A (el)
ES (1) ES2384109T3 (el)
GT (1) GT200600097A (el)
HK (1) HK1118457A1 (el)
HN (1) HN2006009000A (el)
HR (1) HRP20120545T1 (el)
IL (2) IL185552A (el)
MA (1) MA29376B1 (el)
MX (1) MX2007010527A (el)
MY (2) MY177386A (el)
NO (2) NO332368B1 (el)
NZ (1) NZ561004A (el)
PE (2) PE20100740A1 (el)
PL (1) PL1858490T3 (el)
PT (1) PT1858490E (el)
RS (1) RS52374B (el)
RU (2) RU2423970C2 (el)
SG (1) SG160330A1 (el)
SI (1) SI1858490T1 (el)
TN (1) TNSN07336A1 (el)
TW (1) TWI387465B (el)
UA (1) UA93200C2 (el)
UY (1) UY29395A1 (el)
WO (1) WO2006092207A1 (el)
ZA (1) ZA200707320B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
CN102458475B (zh) 2009-05-20 2016-03-30 大日本住友制药株式会社 压制包衣的口腔崩解片
GB2497728A (en) 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
CN103372014B (zh) * 2012-04-26 2015-10-21 齐鲁制药有限公司 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法
CN102727455B (zh) * 2012-07-03 2016-06-29 北京科信必成医药科技发展有限公司 一种他达那非口腔崩解片及其制备方法
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN110193015A (zh) * 2018-02-27 2019-09-03 广州朗圣药业有限公司 一种盐酸伐地那非口腔崩解片及其制备方法
CN108272765B (zh) * 2018-04-26 2021-02-02 江西杏林白马药业股份有限公司 含盐酸伐地那非的药物组合物、口崩片及其制备、应用
SG11202010792TA (en) 2018-05-02 2020-11-27 Ferring Bv Improved pharmaceutical formulations
CN110840851A (zh) * 2019-08-16 2020-02-28 天津仁卫生物医药科技有限公司 一种盐酸伐地那非口腔崩解片及其制备方法
IT201900020350A1 (it) 2019-11-05 2021-05-05 Alpex Pharma Sa Formulazione orodispersibile di vardenafil
WO2021155254A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114848603B (zh) * 2022-04-25 2023-12-12 湖北菲瑞生物药业有限公司 一种伐地那非冻干闪释片及其制备工艺

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
GB790762A (en) 1953-08-28 1958-02-19 Arthur Poole A hydrate of lignocaine hydrochloride and process for making it
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (el) 1963-01-16
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
DK109578A (da) 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
EP0054132B1 (de) 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US4939544A (en) * 1989-11-01 1990-07-03 Eastman Kodak Company Mask for radiation emitting panel
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
EP0524180B1 (en) 1990-04-11 1995-04-26 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
UA46166C2 (uk) 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
US6221402B1 (en) 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
EP1120120A4 (en) 1998-10-05 2009-04-29 Eisai R&D Man Co Ltd TABLETS DISSOLVING DIRECTLY IN MOUTH
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6075028A (en) 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
TWI224966B (en) 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
PL356848A1 (en) 1999-12-24 2004-07-12 Bayer Aktiengesellschaft Novel imidazo[1,3,5]triazinones and the use thereof
CA2406947A1 (en) 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
EP1330250B1 (en) 2000-10-30 2004-05-12 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
CA2437754C (en) 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
CA2449163C (en) 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
KR100530546B1 (ko) 2001-07-27 2005-11-23 아스텔라스세이야쿠 가부시키가이샤 구강내에서 신속하게 붕괴되는 정제용 서방성 미립자가함유된 조성물 및 그의 제조 방법
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
TW200302748A (en) 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
US7939102B2 (en) 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
GB0219516D0 (en) 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
US20040115287A1 (en) 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
MXPA05013202A (es) 2003-06-06 2006-03-09 Ethypharm Sa Tableta de multiples capas oralmente dispersable.
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
KR20070058381A (ko) 2004-04-27 2007-06-08 메디시노바, 인크. 염증성 질환 치료용 페녹시알킬카르복실 산 유도체
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006058250A2 (en) 2004-11-24 2006-06-01 Spi Pharma, Inc. Orally disintegrating compositions
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
MX2008000087A (es) 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
WO2007029376A1 (ja) 2005-09-02 2007-03-15 Fuji Chemical Industry Co., Ltd. 口腔内速崩壊性錠剤

Also Published As

Publication number Publication date
MX2007010527A (es) 2007-11-08
DOP2006000049A (es) 2006-10-31
MY148698A (en) 2013-05-31
NO344546B1 (no) 2020-01-27
IL185552A (en) 2017-06-29
HK1118457A1 (en) 2009-02-13
ATE552828T1 (de) 2012-04-15
AU2006220100B2 (en) 2011-08-18
RU2011111106A (ru) 2012-09-27
ES2384109T3 (es) 2012-06-29
EP1858490B1 (de) 2012-04-11
EP1858490A1 (de) 2007-11-28
ZA200707320B (en) 2009-08-26
CR20130381A (es) 2013-09-12
UY29395A1 (es) 2006-10-02
RU2007135982A (ru) 2009-04-10
AR053552A1 (es) 2007-05-09
MY177386A (en) 2020-09-14
CA2599617A1 (en) 2006-09-08
CN101141950B (zh) 2011-06-08
JP2008531614A (ja) 2008-08-14
CN102198140B (zh) 2016-06-08
UA93200C2 (ru) 2011-01-25
KR101360526B1 (ko) 2014-02-21
TW200640503A (en) 2006-12-01
PT1858490E (pt) 2012-06-19
AR111572A2 (es) 2019-07-31
NO20120203L (no) 2007-09-27
EP2377523A1 (de) 2011-10-19
PE20100740A1 (es) 2010-10-28
RS52374B (en) 2012-12-31
MA29376B1 (fr) 2008-04-01
WO2006092207A1 (de) 2006-09-08
NO332368B1 (no) 2012-09-03
JP5122984B2 (ja) 2013-01-16
BRPI0609375A2 (pt) 2010-03-30
DK1858490T3 (da) 2012-07-23
NO20074848L (no) 2007-09-27
RU2481110C2 (ru) 2013-05-10
HN2006009000A (es) 2010-08-05
RU2423970C2 (ru) 2011-07-20
DE102005009240A1 (de) 2006-09-07
HRP20120545T1 (hr) 2012-07-31
PE20061015A1 (es) 2006-10-20
IL246548A0 (en) 2016-08-31
NZ561004A (en) 2010-12-24
CY1112874T1 (el) 2016-04-13
TNSN07336A1 (en) 2008-12-31
US8613950B2 (en) 2013-12-24
GT200600097A (es) 2006-11-13
US20080249096A1 (en) 2008-10-09
AU2006220100A1 (en) 2006-09-08
PL1858490T3 (pl) 2012-09-28
KR20070110109A (ko) 2007-11-15
CN102198140A (zh) 2011-09-28
IL185552A0 (en) 2008-01-06
SI1858490T1 (sl) 2012-07-31
TWI387465B (zh) 2013-03-01
CR9339A (es) 2007-12-17
US20140186444A1 (en) 2014-07-03
CA2599617C (en) 2012-01-10
CN101141950A (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
SG160330A1 (en) Pharmaceutical forms with improved pharmacokinetic properties
AU2008301614A8 (en) Mutant pyrrolysyl-tRNA synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same
TWI449540B (en) Process for the production of an abuse-proofed dosage form
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
EP2098482A4 (en) SILICON ALLOY AND POWDER, PRODUCTION APPARATUS, PROCESS FOR PRODUCTION, AND AGGLOMERATE
WO2008066558A3 (en) Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines
IL213112A (en) Nemphen hydrochloride dihydrate
WO2009114438A3 (en) Cyclohexanedimethanamine by direct amination of cyclohexanedimethanol
EP2025672A4 (en) 7-ELEMENT HETEROCYCLIC RING, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL USES THEREOF
WO2010060624A3 (de) Trockenverarbeitung und neue formen von lacosamid
WO2010076810A3 (en) A process for the preparation of gefitinib
WO2007081889A8 (en) Production of dolasetron
EP1932829A4 (en) POTASSIUM PERFLUOROALCANESULFONATES AND METHOD FOR PRODUCING THE SAME
WO2008092939A3 (en) Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
IL186862A0 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
WO2011067236A3 (de) Raltegravir-polymorphe
WO2010119450A3 (en) An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts
HK1100424A1 (en) Oral preparations and process for production thereof
ATE437857T1 (de) Neuartige pyridinylaminalkylen- und pyridinyloxalkylen-cyclopropanamine, herstellungsverfahren dafür und pharmazeutische zusammensetzungen damit
GB0617762D0 (en) Processing of sweet sorghum for bioethanol production
MX2010002167A (es) Medicamentos que contienen levaduras.
IL213171A0 (en) Process for production of trans-2,2-dimethyl-3-
EG26960A (en) Process for the production of chlorine dioxide
SI2562170T1 (sl) Postopek za izdelavo 3-(5-(4-(ciklopentiloksi)-2-hidroksibenzoil)-2-((3-okso-2-substituiran- 2,3-dihidro-1,2-benzizoksazol-6-il)metoksi)fenil)propionat estra in intermediata za ta postopek
EA200870236A1 (ru) Моногидрат римонабанта, способ его получения и фармацевтические композиции на его основе